Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 2
1999 4
2000 4
2001 4
2002 2
2003 7
2005 3
2006 10
2007 11
2008 11
2009 6
2010 8
2011 3
2012 12
2013 8
2014 4
2015 2
2016 1
2017 2
2019 3
2020 2
2021 3
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Results by year

Filters applied: . Clear all
Page 1
Hyponatremia in Heart Failure: Pathogenesis and Management.
Rodriguez M, Hernandez M, Cheungpasitporn W, Kashani KB, Riaz I, Rangaswami J, Herzog E, Guglin M, Krittanawong C. Rodriguez M, et al. Curr Cardiol Rev. 2019;15(4):252-261. doi: 10.2174/1573403X15666190306111812. Curr Cardiol Rev. 2019. PMID: 30843491 Free PMC article. Review.
In recent years, a few strategies, such as AVP antagonists (Tolvaptan, Conivaptan, and Lixivaptan), and hypertonic saline in addition to loop diuretics, have been proposed as potentially promising treatment options for this condition. ...
In recent years, a few strategies, such as AVP antagonists (Tolvaptan, Conivaptan, and Lixivaptan), and hypertonic saline in addition …
Vasopressin antagonists.
Lemmens-Gruber R, Kamyar M. Lemmens-Gruber R, et al. Cell Mol Life Sci. 2006 Aug;63(15):1766-79. doi: 10.1007/s00018-006-6054-2. Cell Mol Life Sci. 2006. PMID: 16794787 Review.
The vaptans are vasopressin receptor antagonists with V1a (relcovaptan) or V2 (tolvaptan, lixivaptan) selectivity or non-selective activity (conivaptan) which may be advantageous in some disorders. ...
The vaptans are vasopressin receptor antagonists with V1a (relcovaptan) or V2 (tolvaptan, lixivaptan) selectivity or non-selective ac …
VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist.
Chan PS, Coupet J, Park HC, Lai F, Hartupee D, Cervoni P, Dusza JP, Albright JD, Ru X, Mazandarani H, Tanikella T, Shepherd C, Ochalski L, Bailey T, Lock TY, Ning X, Taylor JR, Spinelli W. Chan PS, et al. Adv Exp Med Biol. 1998;449:439-43. doi: 10.1007/978-1-4615-4871-3_55. Adv Exp Med Biol. 1998. PMID: 10026835 Review. No abstract available.
Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia.
Ghali JK, Zmily HD, Farah JO, Daifallah S. Ghali JK, et al. IDrugs. 2010 Nov;13(11):782-92. IDrugs. 2010. PMID: 21046526 Review.
Lixivaptan (VPA-985), being developed by Biogen Idec and Cardiokine, under license from Wyeth (now part of Pfizer), is a non-peptide, selective vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia associated with heart failure.
Lixivaptan (VPA-985), being developed by Biogen Idec and Cardiokine, under license from Wyeth (now part of Pfizer), is
Treatment of hyponatremia: the role of lixivaptan.
Liamis G, Filippatos TD, Elisaf MS. Liamis G, et al. Expert Rev Clin Pharmacol. 2014 Jul;7(4):431-41. doi: 10.1586/17512433.2014.911085. Epub 2014 Apr 28. Expert Rev Clin Pharmacol. 2014. PMID: 24766294 Review.
The present review considers the role of vasopressin receptor inhibitors (vaptans), focusing on lixivaptan, in the treatment of patients with euvolemic or hypervolemic hyponatremia. Lixivaptan is an oral selective V2 receptor inhibitor, which produces a significantl …
The present review considers the role of vasopressin receptor inhibitors (vaptans), focusing on lixivaptan, in the treatment of patie …
Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985.
Decaux G. Decaux G. J Lab Clin Med. 2001 Jul;138(1):18-21. doi: 10.1067/mlc.2001.116025. J Lab Clin Med. 2001. PMID: 11433224 Clinical Trial.
VPA-985 is an orally active, competitive vasopressin V(2) receptor antagonist that in normal human beings increases water excretion without affecting solute excretion. Whether solute excretion is affected in patients with hyponatremia resulting from inappropriate se
VPA-985 is an orally active, competitive vasopressin V(2) receptor antagonist that in normal human beings increases water excr
Management of hyponatremia.
Lee JJ, Kilonzo K, Nistico A, Yeates K. Lee JJ, et al. CMAJ. 2014 May 13;186(8):E281-6. doi: 10.1503/cmaj.120887. Epub 2013 Dec 16. CMAJ. 2014. PMID: 24344146 Free PMC article. Review. No abstract available.
Lixivaptan: a novel vasopressin receptor antagonist.
Ku E, Nobakht N, Campese VM. Ku E, et al. Expert Opin Investig Drugs. 2009 May;18(5):657-62. doi: 10.1517/13543780902889760. Expert Opin Investig Drugs. 2009. PMID: 19379124 Review.
Studies so far have demonstrated that lixivaptan is efficacious in the correction of hyponatremia in SIADH, heart failure and liver cirrhosis with ascites, and few adverse effects have been noted. Thus, lixivaptan remains a promising therapeutic modality for the tre …
Studies so far have demonstrated that lixivaptan is efficacious in the correction of hyponatremia in SIADH, heart failure and liver c …
The potential role for lixivaptan in heart failure and in hyponatremia.
Zmily HD, Khan NS, Daifallah S, Ghali JK. Zmily HD, et al. Expert Opin Investig Drugs. 2011 Jun;20(6):831-48. doi: 10.1517/13543784.2011.579102. Epub 2011 May 9. Expert Opin Investig Drugs. 2011. PMID: 21548825 Review.
Stimulation of arginine vasopressin (AVP) plays an important role in the development of both hypervolemia and hyponatremia. Lixivaptan is a selective vasopressin type 2 (V(2)) receptor antagonist that has been demonstrated to have the ability to induce aquaresis, the elect …
Stimulation of arginine vasopressin (AVP) plays an important role in the development of both hypervolemia and hyponatremia. Lixivaptan
Evaluation of lixivaptan in euvolemic and hypervolemic hyponatremia and heart failure treatment.
Zmily HD, Alani A, Ghali JK. Zmily HD, et al. Expert Opin Drug Metab Toxicol. 2013 May;9(5):645-55. doi: 10.1517/17425255.2013.783566. Epub 2013 Apr 9. Expert Opin Drug Metab Toxicol. 2013. PMID: 23570283 Review.
INTRODUCTION: Lixivaptan is a selective vasopressin type 2 (V2) receptor antagonist that induces aquaresis, the electrolytes sparing excretion of water. ...AREAS COVERED: The authors review original publications on lixivaptan and summarize their findings. Specifical …
INTRODUCTION: Lixivaptan is a selective vasopressin type 2 (V2) receptor antagonist that induces aquaresis, the electrolytes sparing …
110 results